GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » FamiCord AG (XTER:V3V) » Definitions » ROE % Adjusted to Book Value

FamiCord AG (XTER:V3V) ROE % Adjusted to Book Value : 5.66% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is FamiCord AG ROE % Adjusted to Book Value?

FamiCord AG's ROE % for the quarter that ended in Sep. 2024 was 18.44%. FamiCord AG's PB Ratio for the quarter that ended in Sep. 2024 was 3.26. FamiCord AG's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 5.66%.


FamiCord AG ROE % Adjusted to Book Value Historical Data

The historical data trend for FamiCord AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FamiCord AG ROE % Adjusted to Book Value Chart

FamiCord AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 2.90 -1.92 -12.13 -2.40

FamiCord AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.63 21.27 -3.60 -7.15 5.66

Competitive Comparison of FamiCord AG's ROE % Adjusted to Book Value

For the Medical Care Facilities subindustry, FamiCord AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FamiCord AG's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, FamiCord AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where FamiCord AG's ROE % Adjusted to Book Value falls into.



FamiCord AG ROE % Adjusted to Book Value Calculation

FamiCord AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-9.31% / 3.88
=-2.40%

FamiCord AG's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=18.44% / 3.26
=5.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FamiCord AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of FamiCord AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


FamiCord AG Business Description

Traded in Other Exchanges
Address
Perlickstrase 5, Leipzig, DEU, D-04103
FamiCord AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Company is active in the areas of Cell & Gene therapies and CDMO. It continues to develop from a pure stem cell bank to a more broadly based cell bank that can supply the available patient's own cells for current and future cell therapies.
Executives
Jakub Julian Baran Member of the Management Board
Dr. Alexander Granderath Supervisory Board

FamiCord AG Headlines

No Headlines